Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study.
Rhône-Poulenc Rorer Central Research, Collegeville, PA 19426-0107.
H
H
Slade
J
J
Turner
C
C
Abrams
D
D
Carlo
J
J
Salk
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D005620:Freund's Adjuvant; D015483:HIV Antibodies / Q000097:blood; D016655:HIV Core Protein p24 / Q000276:immunology; D006679:HIV Seropositivity / Q000276:immunology / Q000628:therapy*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D016233:Immunotherapy, Active; D007958:Leukocyte Count; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use
D016915:AIDS Vaccines; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D015164:Vaccines, Inactivated; D005620:Freund's Adjuvant